Halozyme Therapeutics, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
• $750,000,000 — Amended Revolving Credit Facility equal $750,000,000 in total. After giving effect to the A
• $0 — s contemplated therein, the Company had $0 of outstanding borrowings under the Cre
• $650.0 million — to market conditions and other factors, $650.0 million aggregate principal amount of convertib
• $100.0 million — chasers to purchase up to an additional $100.0 million aggregate principal amount of the 2031

Filing Documents

• halo-20251105.htm (8-K) — 39KB
• ex991halo-launchpressrelea.htm (EX-99.1) — 21KB
• halo-20251105_g1.jpg (GRAPHIC) — 15KB
• image_1.jpg (GRAPHIC) — 5KB
• 0001159036-25-000047.txt ( ) — 217KB
• halo-20251105.xsd (EX-101.SCH) — 2KB
• halo-20251105_lab.xml (EX-101.LAB) — 21KB
• halo-20251105_pre.xml (EX-101.PRE) — 12KB
• halo-20251105_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2025, Halozyme Therapeutics, Inc. (the "Company"), Halozyme, Inc. ("Halozyme") and certain other subsidiaries of the Company entered into an Amendment No. 3 (the "Amendment") to the Company's Credit Agreement, dated as of May 24, 2022 (as previously amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"; capitalized terms used but not defined herein shall have the meanings assigned therefor in the Credit Agreement), by and among, inter alios, the Company, Halozyme, the other guarantors party thereto, the lenders party thereto, Bank of America, N.A., as the administrative agent and swing line lender. Pursuant to the Amendment, the Company (a) extended the maturity date of the existing revolving credit facility under the Credit Agreement immediately prior to the effectiveness of the Amendment (the "Existing Revolving Credit Facility" and, as amended and upsized as set forth in clause (b) below, the "Amended Revolving Credit Facility"), and (b) incurred additional revolving credit commitments such that the aggregate amount of commitments under the Amended Revolving Credit Facility equal $750,000,000 in total. After giving effect to the Amendment, the Amended Revolving Credit Facility will mature on the earlier of (a) November 5, 2030 and (b) the Springing Revolver Maturity Date, unless the Amended Revolving Credit Facility is extended prior to such date in accordance with the Credit Agreement. Borrowings under the Amended Revolving Credit Facility bear interest at a rate equal to an applicable margin plus: (a) the applicable Term SOFR (as defined in the Credit Agreement) rate, or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.00%, and (4) 1.00%. The applicable margin for the Ame

01 Other Events

Item 8.01 Other Events. On November 5, 2025, the Company issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $650.0 million aggregate principal amount of convertible senior notes due 2031 (the "2031 Notes") and $650.0 million aggregate principal amount of convertible senior notes due 2032 (the "2032 Notes"). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $100.0 million aggregate principal amount of the 2031 Notes and up to an additional $100.0 million aggregate principal amount of the 2032 Notes. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document Description 99.1 Press release, dated November 5, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Certain schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Halozyme agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. Date: November 5, 2025 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR